Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Cited by (6,845)

Items 101–200 of 6,845

1. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial
   Ahrén, Bo, Masmiquel, Luis, Kumar, Harish, Sargin, Mehmet, Karsbøl, Julie Derving, Jacobsen, Sanja Hald, Chow, Francis · 2017 · The Lancet Diabetes & Endocrinology
2. JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
   Kimura, Kazuo, Kimura, Takeshi, Ishihara, Masaharu, Nakagawa, Yoshihisa, Nakao, Koichi, Miyauchi, Katsumi, Sakamoto, Tomohiro, Tsujita, Kenichi, Hagiwara, Nobuhisa, Miyazaki, Shunichi et al. · 2019 · Circulation Journal
3. 10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2020</i>
   American Diabetes Association · 2020 · Diabetes Care
4. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes
   Aroda, Vanita R., Rosenstock, Julio, Terauchi, Yasuo, Altuntas, Yuksel, Lalic, Nebojsa M., Morales Villegas, Enrique C., Jeppesen, Ole K., Christiansen, Erik, Hertz, Christin L., Haluzík, Martin et al. · 2019 · Diabetes Care
5. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
   2017 · Diabetes Care
6. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
   Nikolaus Marx, Mansoor Husain, Michael Lehrke, Subodh Verma, Naveed A. Sattar · 2022 · Circulation
7. 10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes—2023</i>
   ElSayed, Nuha A., Aleppo, Grazia, Aroda, Vanita R., Bannuru, Raveendhara R., Brown, Florence M., Bruemmer, Dennis, Collins, Billy S., Das, Sandeep R., Hilliard, Marisa E., Isaacs, Diana et al. · 2023 · Diabetes Care
8. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
   Das, Sandeep R., Everett, Brendan M., Birtcher, Kim K., Brown, Jenifer M., Januzzi, James L., Kalyani, Rita R., Kosiborod, Mikhail, Magwire, Melissa, Morris, Pamela B., Neumiller, Joshua J. et al. · 2020 · Journal of the American College of Cardiology
9. Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications
   Eleftheria Papachristoforou, Vaia Lambadiari, Eirini Maratou, Konstantinos Makrilakis · 2020 · Journal of Diabetes Research
10. 10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2019</i>
    American Diabetes Association · 2019 · Diabetes Care
11. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
    Rodbard, Helena W., Rosenstock, Julio, Canani, Luis H., Deerochanawong, Chaicharn, Gumprecht, Janusz, Lindberg, Søren Østergaard, Lingvay, Ildiko, Søndergaard, Anette Luther, Treppendahl, Marianne Bach, Montanya, Eduard et al. · 2019 · Diabetes Care
12. Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk
    Chia, Chee W., Egan, Josephine M., Ferrucci, Luigi · 2018 · Circulation Research
13. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
    Chakhtoura, Marlene, Haber, Rachelle, Ghezzawi, Malak, Rhayem, Caline, Tcheroyan, Raya, Mantzoros, Christos S. · 2023 · eClinicalMedicine
14. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
    Aroda, Vanita R, Bain, Stephen C, Cariou, Bertrand, Piletič, Milivoj, Rose, Ludger, Axelsen, Mads, Rowe, Everton, DeVries, J Hans · 2017 · The Lancet Diabetes &amp; Endocrinology
15. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
    Zhao, Xin, Wang, Minghe, Wen, Zhitong, Lu, Zhihong, Cui, Lijuan, Fu, Chao, Xue, Huan, Liu, Yunfeng, Zhang, Yi · 2021 · Frontiers in Endocrinology
16. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
    Yuliya Lytvyn, Petter Bjornstad, Jacob Allen Udell, Julie A. Lovshin, David Z.I. Cherney · 2017 · Circulation
17. A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives
    Reed, Josh, Bain, Stephen, Kanamarlapudi, Venkateswarlu · 2021 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
18. American D iabetes A ssociation S tandards of M edical C are in D iabetes 2017
    Payal H. Marathe, Helen X. Gao, Kelly L. Close · 2017 · Journal of Diabetes
19. Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
    Dalton Bertolim Précoma, Gláucia Maria Moraes de Oliveira, Antônio Felipe Leite Simão, Óscar Pereira Dutra, Otávio Rizzi Coelho-Filho, Maria Cristina de Oliveira Izar, Rui Póvoa, Isabela de Carlos Back Giuliano, Aristóteles Comte de Alencar Filho, Carlos Alberto Machado et al. · 2019 · Arquivos Brasileiros de Cardiologia
20. 10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes—2024</i>
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., Aleppo, Grazia, Bannuru, Raveendhara R., Bruemmer, Dennis, Collins, Billy S., Das, Sandeep R., Ekhlaspour, Laya, Hilliard, Marisa E., Johnson, Eric L. et al. · 2024 · Diabetes Care
21. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
    Drucker, Daniel J · 2020 · Endocrine Reviews
22. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease
    Guanghong Jia, James R. Sowers · 2021 · Hypertension
23. Discovery, characterization, and clinical development of the glucagon-like peptides
    Drucker, Daniel J., Habener, Joel F., Holst, Jens Juul · 2017 · Journal of Clinical Investigation
24. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
    Capehorn, M.S., Catarig, A.-M., Furberg, J.K., Janez, A., Price, H.C., Tadayon, S., Vergès, B., Marre, M. · 2020 · Diabetes &amp; Metabolism
25. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial
    Rosenstock, Julio, Allison, Dale, Birkenfeld, Andreas L., Blicher, Thalia Marie, Deenadayalan, Srikanth, Jacobsen, Jacob Bonde, Serusclat, Pierre, Violante, Rafael, Watada, Hirotaka, Davies, Melanie et al. · 2019 · JAMA
26. Reducing the Global Burden of Cardiovascular Disease, Part 2
    Darryl P. Leong, Philip G. Joseph, Martin McKee, Sonia Savitri Anand, Koon Kang Teo, Jon-David Schwalm, Salim Yusuf · 2017 · Circulation Research
27. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
    Friedrichsen, Martin, Breitschaft, Astrid, Tadayon, Sayeh, Wizert, Alicja, Skovgaard, Dorthe · 2021 · Diabetes, Obesity and Metabolism
28. Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis
    Zin Zin Htike, Francesco Zaccardi, Dimitris Papamargaritis, David R. Webb, Kamlesh Khunti, Melanie Jane Davies · 2016 · Diabetes Obesity and Metabolism
29. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    McGuire, Darren K., Marx, Nikolaus, Mulvagh, Sharon L., Deanfield, John E., Inzucchi, Silvio E., Pop-Busui, Rodica, Mann, Johannes F.E., Emerson, Scott S., Poulter, Neil R., Engelmann, Mads D.M. et al. · 2025 · New England Journal of Medicine
30. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
    Rodbard, Helena W, Lingvay, Ildiko, Reed, John, de la Rosa, Raymond, Rose, Ludger, Sugimoto, Danny, Araki, Eiichi, Chu, Pei-Ling, Wijayasinghe, Nelun, Norwood, Paul · 2018 · The Journal of Clinical Endocrinology &amp; Metabolism
31. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
    Muskiet, Marcel H. A., Tonneijck, Lennart, Smits, Mark M., van Baar, Michaël J.B., Kramer, Mark H. H., Hoorn, Ewout J., Joles, Jaap A., van Raalte, Daniël H. · 2017 · Nature Reviews Nephrology
32. 10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2021</i>
    American Diabetes Association · 2021 · Diabetes Care
33. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
    Gilbert, Matthew P., Pratley, Richard E. · 2020 · Frontiers in Endocrinology
34. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
    Sean Lee Zheng, Alistair Roddick, Rochan Agha-Jaffar, Matthew James Shun-Shin, Dárrel P. Francis, Nick S. Oliver, Karim M. Meeran · 2018 · JAMA
35. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
    Rodica Pop‐Busui, James L. Januzzi, Dennis Bruemmer, Sonia Butalia, Jennifer B. Green, William B. Horton, Colette M. Knight, Moshe Levi, Neda Rasouli, Caroline Regina Richardson · 2022 · Diabetes Care
36. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
    Hinnen, Deborah · 2017 · Diabetes Spectrum
37. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
    American Diabetes Association · 2018 · Diabetes Care
38. 2020 Clinical practice guidelines for Chronic heart failure
    Russian Society of Cardiology · 2020 · Russian Journal of Cardiology
39. 11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetes—2021</i>
    American Diabetes Association · 2021 · Diabetes Care
40. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
    Heerspink, Hiddo J.L., Kosiborod, Mikhail, Inzucchi, Silvio E., Cherney, David Z.I. · 2018 · Kidney International
41. The evolving story of incretins ( <scp>GIP</scp> and <scp>GLP</scp> ‐1) in metabolic and cardiovascular disease: A pathophysiological update
    Nauck, Michael A., Quast, Daniel R., Wefers, Jakob, Pfeiffer, Andreas F. H. · 2021 · Diabetes, Obesity and Metabolism
42. The cardio-renal-metabolic connection: a review of the evidence
    Marassi, Marella, Fadini, Gian Paolo · 2023 · Cardiovascular Diabetology
43. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
    Butler, Javed, Shah, Sanjiv J, Petrie, Mark C, Borlaug, Barry A, Abildstrøm, Steen Z, Davies, Melanie J, Hovingh, G Kees, Kitzman, Dalane W, Møller, Daniél Vega, Verma, Subodh et al. · 2024 · The Lancet
44. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG outcome randomised, placebo-controlled trial
    Cherney, David Z I, Zinman, Bernard, Inzucchi, Silvio E, Koitka-Weber, Audrey, Mattheus, Michaela, von Eynatten, Maximilian, Wanner, Christoph · 2017 · The Lancet Diabetes &amp; Endocrinology
45. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
    Zinman, Bernard, Bhosekar, Vaishali, Busch, Robert, Holst, Ingrid, Ludvik, Bernhard, Thielke, Desirée, Thrasher, James, Woo, Vincent, Philis-Tsimikas, Athena · 2019 · The Lancet Diabetes &amp; Endocrinology
46. 11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetes−2020</i>
    American Diabetes Association · 2020 · Diabetes Care
47. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials
    Bettge, Karolin, Kahle, Melanie, Abd El Aziz, Mirna S., Meier, Juris J., Nauck, Michael A. · 2017 · Diabetes, Obesity and Metabolism
48. Epidemiology and modifiable risk factors for atrial fibrillation
    Adrian D. Elliott, Melissa E. Middeldorp, Isabelle C. Van Gelder, Christine M. Albert, Prashanthan Sanders · 2023 · Nature Reviews Cardiology
49. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
    William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter et al. · 2017 · Diabetes Care
50. 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association
    Cheryl Bushnell, Walter N. Kernan, Anjail Zarinah Sharrief, Seemant Chaturvedi, John W. Cole, William K. Cornwell, Christine Cosby-Gaither, Sarah Doyle, Larry B. Goldstein, Olive C. Lennon et al. · 2024 · Stroke
51. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond
    Hans‐Peter Hammes · 2017 · Diabetologia
52. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease
    Alla V. Mitrofanova, Sandra Merscher, Alessia Fornoni · 2023 · Nature Reviews Nephrology
53. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
    Cena, Hellas, Chiovato, Luca, Nappi, Rossella E · 2020 · The Journal of Clinical Endocrinology &amp; Metabolism
54. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
    Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, Katherine R. Tuttle, Joshua J. Neumiller, Connie M. Rhee, Sylvia E. Rosas, Peter R Rossing, George L. Bakris · 2022 · Kidney International
55. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
    Jelena P. Seferović, Brian Lee Claggett, Sara Bretschger Seidelmann, Ellen W. Seely, Milton Packer, Michael R. Zile, Jean Lucien Rouleau, Karl B Swedberg, Martin P. Lefkowitz, Victor Chengwei Shi et al. · 2017 · The Lancet Diabetes & Endocrinology
56. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
    Mosenzon, Ofri, Blicher, Thalia Marie, Rosenlund, Signe, Eriksson, Jan W, Heller, Simon, Hels, Ole Holm, Pratley, Richard, Sathyapalan, Thozhukat, Desouza, Cyrus, Abramof, R et al. · 2019 · The Lancet Diabetes &amp; Endocrinology
57. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
    Ryan, Donna H., Lingvay, Ildiko, Deanfield, John, Kahn, Steven E., Barros, Eric, Burguera, Bartolome, Colhoun, Helen M., Cercato, Cintia, Dicker, Dror, Horn, Deborah B. et al. · 2024 · Nature Medicine
58. Progress and challenges in anti-obesity pharmacotherapy
    Bessesen, Daniel H, Van Gaal, Luc F · 2018 · The Lancet Diabetes &amp; Endocrinology
59. Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
    Sattar, Naveed, McGuire, Darren K., Pavo, Imre, Weerakkody, Govinda J., Nishiyama, Hiroshi, Wiese, Russell J., Zoungas, Sophia · 2022 · Nature Medicine
60. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review
    Sneha Annie Sebastian, Inderbir Padda, Gurpreet Johal · 2023 · Current Problems in Cardiology
61. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
    Badve, Sunil V, Bilal, Anika, Lee, Matthew M Y, Sattar, Naveed, Gerstein, Hertzel C, Ruff, Christian T, McMurray, John J V, Rossing, Peter, Bakris, George, Mahaffey, Kenneth W et al. · 2025 · The Lancet Diabetes &amp; Endocrinology
62. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
    Grunvald, Eduardo, Shah, Raj, Hernaez, Ruben, Chandar, Apoorva Krishna, Pickett-Blakely, Octavia, Teigen, Levi M., Harindhanavudhi, Tasma, Sultan, Shahnaz, Singh, Siddharth, Davitkov, Perica · 2022 · Gastroenterology
63. Japanese Clinical Practice Guideline for Diabetes 2019
    Eiichi Araki, Atsushi Goto, Tatsuya Kondo, Mitsuhiko Noda, Hiroshi Noto, Hideki Origasa, Haruhiko Osawa, Akihiko Taguchi, Yukio Tanizawa, Kazuyuki Tobe et al. · 2020 · Journal of Diabetes Investigation
64. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Das, Sandeep R., Echouffo-Tcheugui, Justin B. et al. · 2025 · Diabetes Care
65. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk
    Emir M. Muzurović, Dimitri P. Mikhailidis, Christos Socrates Mantzoros · 2021 · Metabolism
66. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
    Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Faiez M. Zannad · 2017 · JAMA Cardiology
67. Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
    Sandra Rayego‐Mateos, José Luis Morgado‐Pascual, Lucas Opazo-Ríos, Melania Guerrero‐Hue, Cristina García‐Caballero, Cristina Vázquez‐Carballo, Sebastián Mas, Ana Belen Sanz, Carmen Herencia, Sergio A. Mezzano et al. · 2020 · International Journal of Molecular Sciences
68. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial
    Athinarayanan, Shaminie J., Adams, Rebecca N., Hallberg, Sarah J., McKenzie, Amy L., Bhanpuri, Nasir H., Campbell, Wayne W., Volek, Jeff S., Phinney, Stephen D., McCarter, James P. · 2019 · Frontiers in Endocrinology
69. Peptide chemistry toolbox – Transforming natural peptides into peptide therapeutics
    Miloš Erak, Kathrin Bellmann‐Sickert, Sylvia Els‐Heindl, Annette Gabriele Beck‐Sickinger · 2018 · Bioorganic & Medicinal Chemistry
70. GLP-1 Receptor Expression Within the Human Heart
    Baggio, Laurie L, Yusta, Bernardo, Mulvihill, Erin E, Cao, Xiemin, Streutker, Catherine J, Butany, Jagdish, Cappola, Thomas P, Margulies, Kenneth B, Drucker, Daniel J · 2018 · Endocrinology
71. Macrophage functions in lean and obese adipose tissue
    Dylan D. Thomas, Caroline Margaret Apovian · 2017 · Metabolism
72. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
    Ray, Kausik K, Colhoun, Helen M, Szarek, Michael, Baccara-Dinet, Marie, Bhatt, Deepak L, Bittner, Vera A, Budaj, Andrzej J, Diaz, Rafael, Goodman, Shaun G, Hanotin, Corinne et al. · 2019 · The Lancet Diabetes &amp; Endocrinology
73. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Das, Sandeep R., Everett, Brendan M., Birtcher, Kim K., Brown, Jenifer M., Cefalu, William T., Januzzi, James L., Kalyani, Rita Rastogi, Kosiborod, Mikhail, Magwire, Melissa L., Morris, Pamela B. et al. · 2018 · Journal of the American College of Cardiology
74. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
    Rowlands, Jordan, Heng, Julian, Newsholme, Philip, Carlessi, Rodrigo · 2018 · Frontiers in Endocrinology
75. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
    Vilsbøll, Tina, Bain, Stephen C., Leiter, Lawrence A., Lingvay, Ildiko, Matthews, David, Simó, Rafael, Helmark, Ida Carøe, Wijayasinghe, Nelun, Larsen, Michael · 2018 · Diabetes, Obesity and Metabolism
76. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
    Hathaway, Jimena Tatiana, Shah, Madhura P., Hathaway, David B., Zekavat, Seyedeh Maryam, Krasniqi, Drenushe, Gittinger, John W., Cestari, Dean, Mallery, Robert, Abbasi, Bardia, Bouffard, Marc et al. · 2024 · JAMA Ophthalmology
77. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
    Thomas Ray Einarson, Annabel Acs, Craig Ludwig, Ulrik Haagen Panton · 2018 · Value in Health
78. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
    Arnold, Suzanne V., Bhatt, Deepak L., Barsness, Gregory W., Beatty, Alexis L., Deedwania, Prakash C., Inzucchi, Silvio E., Kosiborod, Mikhail, Leiter, Lawrence A., Lipska, Kasia J., Newman, Jonathan D. et al. · 2020 · Circulation
79. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
    Lingvay, Ildiko, Catarig, Andrei-Mircea, Frias, Juan P, Kumar, Harish, Lausvig, Nanna L, le Roux, Carel W, Thielke, Desirée, Viljoen, Adie, McCrimmon, Rory J · 2019 · The Lancet Diabetes &amp; Endocrinology
80. Obesity and cardiovascular disease: An ESC clinical consensus statement
    Koskinas, Konstantinos C, Van Craenenbroeck, Emeline M, Antoniades, Charalambos, Blüher, Matthias, Gorter, Thomas M, Hanssen, Henner, Marx, Nikolaus, McDonagh, Theresa A, Mingrone, Geltrude, Rosengren, Annika et al. · 2024 · European Heart Journal
81. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
    Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, Yoshio Fujioka, Yasushi Ishigaki, Shinji Koba, Hirotoshi Ohmura, Tetsuo Shoji, Koutaro Yokote, Hiroshi Yoshida et al. · 2023 · Journal of Atherosclerosis and Thrombosis
82. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
    American Diabetes Association · 2017 · Diabetes Care
83. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Yun, Jae-Seung, Ko, Seung-Hyun · 2021 · Metabolism
84. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
    Mantovani, Alessandro, Petracca, Graziana, Beatrice, Giorgia, Csermely, Alessandro, Lonardo, Amedeo, Targher, Giovanni · 2021 · Metabolites
85. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review
    Stephen Charles Bain, Michael A. Klufas, Allen C. Ho, David R Matthews · 2018 · Diabetes Obesity and Metabolism
86. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
    Ma, Xiaoxuan, Liu, Zhenghong, Ilyas, Iqra, Little, Peter J., Kamato, Danielle, Sahebka, Amirhossein, Chen, Zhengfang, Luo, Sihui, Zheng, Xueying, Weng, Jianping et al. · 2021 · International Journal of Biological Sciences
87. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
    Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2019 · Endocrine Practice
88. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
    Aroda, V.R., Ahmann, A., Cariou, B., Chow, F., Davies, M.J., Jódar, E., Mehta, R., Woo, V., Lingvay, I. · 2019 · Diabetes &amp; Metabolism
89. Safety of Semaglutide
    Smits, Mark M., Van Raalte, Daniël H. · 2021 · Frontiers in Endocrinology
90. 11. Chronic Kidney Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2022</i>
    American Diabetes Association Professional Practice Committee · 2022 · Diabetes Care
91. Mapping the effectiveness and risks of GLP-1 receptor agonists
    Xie, Yan, Choi, Taeyoung, Al-Aly, Ziyad · 2025 · Nature Medicine
92. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
    Sandra Naaman, George L. Bakris · 2023 · Diabetes Care
93. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
    Michael Albrecht Nauck, Jakob Wefers, Juris Jendrik Meier · 2021 · The Lancet Diabetes & Endocrinology
94. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
    Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana M. Isaacs, Eric L. Johnson et al. · 2022 · Diabetes Care
95. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
    Eberly, Lauren A., Yang, Lin, Essien, Utibe R., Eneanya, Nwamaka D., Julien, Howard M., Luo, Jing, Nathan, Ashwin S., Khatana, Sameed Ahmed M., Dayoub, Elias J., Fanaroff, Alexander C. et al. · 2021 · JAMA Health Forum
96. Cardiomyopathy in obesity, insulin resistance and diabetes
    Michinari Nakamura, Junichi Sadoshima · 2019 · The Journal of Physiology
97. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
    Katherine R. Tuttle, Frank Chip Brosius, Sharon G. Adler, Matthias Kretzler, Ravindra L. Mehta, James Alan Tumlin, Yoshiya Tanaka, Masakazu Haneda, Jiajun Liu, Maria E. Silk et al. · 2017 · Nephrology Dialysis Transplantation
98. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
    Nevola, Riccardo, Epifani, Raffaella, Imbriani, Simona, Tortorella, Giovanni, Aprea, Concetta, Galiero, Raffaele, Rinaldi, Luca, Marfella, Raffaele, Sasso, Ferdinando Carlo · 2023 · International Journal of Molecular Sciences
99. Therapeutic pipeline in nonalcoholic steatohepatitis
    Vuppalanchi, Raj, Noureddin, Mazen, Alkhouri, Naim, Sanyal, Arun J. · 2021 · Nature Reviews Gastroenterology &amp; Hepatology
100. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
     Pieber, Thomas R, Bode, Bruce, Mertens, Ann, Cho, Young Min, Christiansen, Erik, Hertz, Christin L, Wallenstein, Signe O R, Buse, John B, Akın, S, Aladağ, N et al. · 2019 · The Lancet Diabetes &amp; Endocrinology